Research programme: Syk kinase inhibitors - Dynamix/Teva
Alternative Names: DNX-02070; DNX-2000; DNX-2070Latest Information Update: 16 Jul 2016
Price :
$50 *
At a glance
- Originator Dynamix Pharmaceuticals
- Developer Dynamix Pharmaceuticals; Teva Pharmaceutical Industries
- Class Small molecules
- Mechanism of Action Syk kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Autoimmune disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Autoimmune-disorders in Israel
- 14 Jun 2011 Preclinical trials in Autoimmune disorders in Israel (unspecified route)